{'fraction_non_alphanumeric': 0.02768166089965398, 'fraction_numerical': 0.01384083044982699, 'mean_word_length': 5.370044052863436, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Early diagnosis of myocardial infarction.

The assertion that “giving thrombolytic agents on the basis of clinical features alone will confer no benefit in the absence of ST segment elevation” needs to be qualified to include bundle branch block (BBB) as an even stronger indication for thrombolytic treatment, given the fact that the 23.6% mortality risk of BBB related myocardial infarction is significantly and favourably modified by this treatment. The paradox is that the masking of electrocardiographic (ECG) criteria of myocardial infarction by BBB also increases the risk of inappropriate thrombolysis, rendering patients in this subgroup the ones in greatest need of a short time window marker, which, however, should complement but not replace the ECG in the diagnostic process. For this purpose, myoglobin may be preferable to troponin, given the fact that three to four hours after onset of suspected myocardial infarction, this variable is acknowledged to have superior sensitivity (68– 77% v 37–43%) and negative predictive value (84–89% v 72–77%). Of all the therapeutic time windows, however, the earliest ones are prognostically the most important, thereby mandating sole reliance on ECG stigmata for validation of suspected myocardial infarction until such time that an enzymatic marker becomes available also for the < 3 hour time window, serving, once again, to complement but not replace the ECG in clinical decision making.